搜索优化
English
搜索
图片
视频
地图
资讯
购物
Copilot
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 30 天
时间不限
过去 1 小时
过去 24 小时
过去 7 天
按时间排序
按相关度排序
PharmaTimes
23 小时
Owlstone Medical announces $27 million USD first close in Series E financing round
Owlstone Medical has announced a first close of $27 million (circa £22 million) in its Series E financing round. The round ...
PharmaTimes
23 小时
Oxford Drug Design achieves in vivo validation for novel cancer treatment
Oxford Drug Design, the Oxford-based AI drug discovery company, has announced further in vivo validation for its first-in-class cancer treatment approach. The company is developing novel treatments ...
PharmaTimes
1 天
Pheno Therapeutics granted trial authorisation for MS candidate
Pheno Therapeutics Limited has received clinical trial authorisation (CTA) from the UK’s MHRA for its lead candidate, PTD802.
PharmaTimes
1 天
Grifols pioneers high-tech analysis of plasma bank to detect Parkinson’s disease
Grifols has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to identify plasma-based ...
PharmaTimes
3 天
AI set to revolutionise pharmaceutical R&D says GlobalData
AI is poised to significantly lower pharmaceutical R&D costs through efficient drug discovery, optimised clinical trials, and ...
PharmaTimes
3 天
Gilead and LEO Pharma partner to develop oral STAT6 program
Gilead Sciences and LEO Pharma have announced a strategic partnership to advance LEO Pharma’s oral STAT6 program. This ...
PharmaTimes
7 天
New therapy hope for prostate cancer patients
Prostate cancer resistant to hormone therapy could soon have a new treatment option. The Institute of Cancer Research (ICR), ...
PharmaTimes
7 天
NICE recommends olaparib for BRCA-mutated breast cancer treatment
The National Institute for Health and Care Excellence (NICE) has given a positive recommendation for Lynparza (olaparib) for ...
PharmaTimes
8 天
Cambridge Cognition highlights positive Cantab results
Cambridge Cognition believes these findings highlight Cantab’s effectiveness in measuring cognitive performance improvements.
PharmaTimes
8 天
Angelini Ventures co-leads Series A financing in Neumirna Therapeutics
Angelini Ventures has co-led a €20 million Series A financing round in Neumirna Therapeutics. The financing, also led by ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈